-
Product Insights
Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. The Anaplastic Astrocytoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage...
-
Product Insights
Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chondrosarcoma is a cancer whose tumor cells produce pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, and changes in urination. Treatment includes chemotherapy and radiation therapy. The Chondrosarcoma pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape. Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the...
-
Product Insights
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. The activity of CDK2 is especially critical during the G1 to S phase transition. The Cyclin Dependent Kinase 2 pipeline drugs market research report provides comprehensive information on the therapeutics under development for Cyclin Dependent Kinase 2, complete with analysis by stage of development, drug target, mechanism of action (MoA), route...
-
Product Insights
Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pontine gliomas are highly aggressive and difficult-to-treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing. The pontine glioma pipeline drugs market research report provides comprehensive information on the therapeutics under development for pontine...
-
Product Insights
20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The 20s Proteasome pipeline drugs market research report outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects.
-
Product Insights
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The Prostaglandin E2 receptor 4 (EP4) pipeline market research report provides comprehensive information on the therapeutics under development for Prostaglandin E2 receptor 4 (EP4), complete with...
-
Product Insights
Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. The Pheochromocytoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Fallopian Tube Cancer symptoms may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis. The Fallopian Tube Cancer pipeline drugs market research report provides an analysis of the Fallopian Tube Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the...
-
Product Insights
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
 Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy. The Hairy Cell Leukemia pipeline drugs market research report outlays comprehensive information on the Hairy Cell Leukemia targeted therapeutics, complete with analysis...